Healthcare Capital & Connections Summit

2017 Summit

The Healthcare Capital & Connections Summit was founded in 2014 to connect US and Chinese companies and investors. In 2017, attendees also included companies and investors from Canada, Europe and across Asia. The Summit provides opportunities to share cross-border best practices and make connections to facilitate deals.

2017 Summit Agenda

Day One: Tuesday, September 12, 2017

Day Two: Wednesday, September 13, 2017

09:00 – 09:15

Welcome and Opening Remarks

David Sabow, Head of Life Science, Client Funds & Products, Silicon Valley Bank

Chen Yu, Managing Partner, Vivo Capital

09:15 – 10:00

China’s Healthcare Market – Impact of Recent Regulatory Changes
This presentation will explore the regulatory, demographic, economic and intellectual property reforms that will shape China’s healthcare system through the rest of the 21st Century, as well as present a perspective on the potential winners and losers in this transition.Moderator: Qiang Li, Partner, DLA PiperPanelists:

The Emergence of China Biotech
No longer just a big market for generics, China is at the very beginning of becoming a leader in Biotech innovation on a global scale. What role is China likely to play in the future and what are the implications for the global Biotech community.Moderator: Jielun Zhu, Head of Healthcare Investment Banking Asia, JefferiesPanelists:

Dr. Scott Liu, President & CEO of Shanghai, Henlius Biotech Inc.

Ming Guo, PhD, Co-Founder, President & COO, Ascentage Pharma

Ke Geng, Partner, O’Melveny

10:45 – 11:15

Strategic Priorities in China: View of Biopharma Companies
Over this past year there have been a number of high-profile cross-border collaborations and licensing deals between the West and China in the biomedical sector. However, companies operating in China must also navigate a broad array of challenges. This panel will explore the opportunities and challenges of the biopharmaceutical market in China and discuss the different strategies companies employ to be successful in the world’s second largest economy.

Donnie McGrath, Chief of Corporate Strategy and Business Development, Biohaven

Werner Cautreels, CEO, Selecta Biosciences

11:15 – 12:00

Cross Border M & A/Licensing— The Current State of Affairs
Increasingly Chinese corporates are actively investing, licensing and acquiring global life science & healthcare technologies. Hear from leading business development professionals on the process and the key contributors to success and failure.Moderator: Andy Clayton, Principal & Head of Asia Healthcare Investment Banking, Piper JaffrayPanelists:

Sammy Jiang, Vice President of International Business & Strategy, Luye Pharma Group

Jason Zhang, Managing Director, International Investment and Business Development, Humanwell

Company Presentations and 1 on 1 Meetings Hear presentations from some of the most innovative Chinese and International life science and healthcare entrepreneurs. Conduct 1 on 1 meetings with investors and strategics, organized via Meeting Mojo software platform.

Day Three: Thursday, September 14, 2017

09:00 – 09:30

The Impact of China’s Reimbursement Landscape on Medtech Growth
The payment environment in China is rapidly evolving with caps on drug and device mark-ups, a downward trend in tender pricing and domestic procurement preferences. In addition, national payment reform is being considered alongside joint provincial procurement and DRG pilots. This panel will explore the impact of the evolving payment environment on China’s doctors and patients, as well as both domestic and international manufacturers.Moderator: Helen Chen, Managing Director, Head of China Life Sciences, L.E.K. ConsultingPanelists:

Helen Zhang, AdvaMed Member

Michael Chang, Managing Director, Vivo Ventures

09:30 – 10:15

Currency Restrictions & Trade Policy—Impact on Cross Border Deals
In an environment of volatile trade policy and pressure on economic growth it has become increasingly challenging to move capital out of China. What is driving this, what are the best practices in navigating the current climate and what will influence this in the future.Moderator: Christina Zhang, Partner in Charge – Shanghai, CooleyPanelists:

Accessing Investment Capital in China
Chinese venture capital has become an increasingly prevalent source of capital for global life science and healthcare innovation. What are Chinese VCs looking for? How does this compare and contrast to Sandhill Road and what do global executives need to know in order to navigate this process successfully?Moderator: Lu Huang, Managing Director, MorningsidePanelists:

Don Xu, Lynx Financial

Ching Zhu, Managing Partner, 6 Dimensions Capital

Chelsea Zhang, Partner, Ping An Ventures

Dr. Karen Liu, Founding Partner, 3E Bioventures

11:00 – 11:45

Working with China A-Share Listed Companies
China's A-share companies are increasingly looking overseas for partnerships, investments, and acquisition opportunities. We will discuss what is driving this interest, what they are looking for, the various options to work together, the evolving Chinese regulatory environment, the challenges/pitfalls and successful stories to overcome them, and the forecast for the future.Moderator Irene Hong, CEC CapitalPanelists:

Medical Devices: The Global State of the Sector
The importance of Medical Device interventions continues to increase as the global healthcare community seeks alternatives to a lifetime of costly therapies. Despite challenges created by continued consolidation and a more constrained US venture capital environment, innovation in the sector continues to thrive and the environment is ripe for creative cross-border transactions.Speaker Matt Steere, Managing Director, Life Sciences Investment Banking, Canaccord Genuity

13:15 – 13:45

Next Frontiers of Global Innovation: Ophthalmology Futures
Hosted by Ophthalmology Futures European and Asian Forums and kindly supported by the Santen Pharmaceutical (China) Co Ltd with the assistance of Carl Zeiss Meditec Inc, this panel will explore the diverse world of ophthalmic innovation and the immense investment and business opportunities that it offers. Ophthalmology involves the highest level of biotechnology and device technology miniaturized to a small and unique organ. For the savvy investor, for businesses inside and outside China who are interested in the vast market and development capability that this country can offer, ophthalmology promises to be a rapidly expanding and rewarding area.

Company Presentations and 1 on 1 Meetings
Hear presentations from some of the most innovative Chinese and international life science and healthcare entrepreneurs. Conduct 1 on 1 meetings with investors and strategics, organized via Meeting Mojo software platform.